DexCom reports Q2 sales of $1.004B, up 15% YoY, with adjusted EPS of $0.43, beating the $0.39 consensus. Despite lowering 2024 sales guidance to $4.00-$4.05B, William Blair maintains an Outperform rating, anticipating strong market growth through 2027.
Read more